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Summary There is increasing experimental evidence to suggest that expression of 06-alkylguanine-DNA-
alkyltransferase (ATase) is a major factor in resistance to dacarbazine (DTIC). We recently demonstrated a
progressive ATase depletion in human peripheral lymphocytes with nadir levels occurring at 4-6 h after DTIC
administration (Lee et al., 1991). Therefore in an attempt to improve the clinical response rate of DTIC,
fotemustine was administered 4 h after DTIC administration; since in the case of fotemustine, ATase removes
the chloroethyl lesions from the 06-position of guanine, thereby preventing the formation of the cytotoxic
cross-links. Sixty patients with widely metastatic melanoma received DTIC at 400, 500 or 800 mg m-2
followed by fotemustine (100 mg m') at 4 h after DTIC administration. Treatment was repeated every 28
days with a total of 169 cycles of chemotherapy administered; 75, 57 and 37 treatment cycles with 400, 500
and 800mg m2 DTIC groups respectively. Eighteen of the 60 patients responded (with three complete
response); response rates were linearly related to dose, being 24%, 30% and 40% in patients receiving 400, 500
and 800 mg m-2 of DTIC respectively and the overall response rate was 30%. Median survival was 3.6 months
(range, 1- 15 months) with no statistically significant difference between the different DTIC treatment groups
(P = 0.67). Nine patients are alive at 5 to 26 months (median 10 months); three patients with no tumour and
five patients with stable disease. A statistically significant relationship was seen between the development of
severe haematological toxicity (WHO > 3) with increasing dosage of DTIC and significant subclinical pul-
monary damage was seen in 11 patients where the lung function was monitored during the course of
treatment. In conclusion, it appears that with this small group of patients, escalation of DTIC dosage might
not significantly affect response rates but does increase haematological toxicity. The present study provides a
framework for other studies in an attempt to modulate ATase-mediated drug resistance in tumour tissues but
the associated toxicity will need careful monitoring.
Dimethyl-triazeno-imidazole-carboxamide (Dacarbazine, DT-
IC) is still considered one of the more effective chemothera-
peutic agents used in the treatment of advanced disseminated
melanoma and regularly produces a response rate of approx-
imately 20% (Comis, 1976; Balch et al., 1989). After DTIC,
the nitrosoureas are considered the second most effective
agents and produce an approximately 15% response rate
(Comis, 1976; Balch et al., 1989). The doses of DTIC used
have ranged from 2 mg kg-' for 10 days to 1450 mg m-2 as a
single bolus every 4 to 6 weeks (Cowan & Bergsagel, 1971;
Comis, 1976; Mastrangelo et al., 1982). Infusion of DTIC
over 24 h has also been explored (Thatcher et al., 1985). The
most popular DTIC schedule consists of 250 mgm2 daily
intravenously for 5 consecutive days, treatment being repeat-
ed every 3-4 weeks (Mastrangelo et al., 1982; Geeraerts &
Nathanson, 1986). Combination chemotherapy has added
little to the response rate and survival duration and fre-
quently resulted in significant increases in toxicity (Mast-
rangelo et al., 1982; Geeraerts & Nathanson, 1986; McClay
& Mastrangelo, 1988).
DTIC undergoes metabolic N-demethylation to give the
cytotoxic monomethyl triazene, 5-(3-methyl-l-triazeno)imida-
zole-4-carboxamide (MTIC) which methylates DNA, produc-
ing among 12 other lesions, 06-methylguanine (Meer et al.,
1986). There is increasing evidence to suggest that o6_
methylguanine is the principal cytotoxic event following
DTIC and that 06-alkylguanine-DNA alkyltransferase (AT-
ase) expression may be a major factor in cellular resistance to
such agents (D'Incalci et al., 1988; Pegg, 1990). ATase is able
to transfer the methyl group from the 06 position of guanine
to an internal cysteine residue in an auto-inactivating stoich-
iometric reaction. Experimental models using ATase-deficient
cell lines or xenografts show them to be more sensitive to
DTIC than lines or xenografts with high activity (Hayward &
Parsons, 1984; Gibson et al., 1986; Catapano et al., 1987;
D'Incalci et al., 1988; Lunn & Harris, 1988; Foster et al.,
1990). The strongest evidence for the cytotoxic effects of
06-alkylguanine in DNA comes from ATase cDNA transfec-
tion experiments which show that expression of prokaryotic
or eukaryotic ATase cDNA in mammalian cells protects
them against the toxic effects to these agents (Brennand &
Margison, 1986; Kataoka et al., 1986; Samson et al., 1986;
Kaina et al., 1991).
We recently demonstrated a progressive ATase depletion in
human peripheral lymphocytes with nadir ATase levels oc-
curring at 4-6 h after DTIC administration (Lee et al.,
1991). Assuming that a similar depletion effect occurs in the
tumour cells, an enhanced therapeutic effect might be ob-
tained if a nitrosourea is administered at the nadir of ATase
activity following DTIC treatment since in the case of nit-
rosoureas, ATase removes the chloroethyl lesions from the
06-position of guanine, thereby preventing the formation of
cytotoxic cross-links (D'Incalci et al., 1988; Pegg, 1990).
Therefore in an attempt to improve the clinical response rate
of DTIC, fotemustine was administered at 4h after DTIC
administration, the time which was shown to be associated
with maximal ATase depletion in the peripheral blood lym-
phocytes. Fotemustine is a new drug containing a phos-
phonoalanine carrier grafted to the nitrosourea radical and it
has shown promising clinical efficacy (Jacquillat et al., 1990).
The present study evaluates and compares the clinical results
of using three different doses of DTIC (400, 500 and
800 mg m2) with fotemustine (100 mg m-2).
Materials and methods
Sixty patients with widely metastatic malignant melanoma
were entered into the study protocol. The protocol required
histological documentation of metastatic melanoma, measur-
able metastasis, Karnofsky index > 50, a white blood count
> 4.0 x I091', a platelet count > 100 x I0 1'-, a haemo-
globin > 11 g 1'- and no major disturbance of renal or
hepatic biochemistry. Local ethical approval was obtained
for the study.
The median age was 55 years (range, 17-75 years), and
there was 28 males and 32 females. The median time from
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surgery to first metastasis was 3 years (range 0 to 12 years).
Number of patients with metastatic sites were: five patients
with non-visceral sites, 21 patients with visceral sites and 34
patients with both visceral and non-visceral sites. Twelve
patients had prior chemotherapy and 13 patients had local-
ised radiotherapy, but other metastatic sites were available
for evaluation in the study.
Patients received DTIC at 400, 500 or 800 mg m-2 by i.v.
infusion over 10min followed by fotemustine (100 mgm-2)
over 30 min at 4 h after DTIC. Treatment was repeated every
28 days. A total of 169 cycles of chemotherapy were ad-
ministered; 75, 57 and 37 treatment cycles in the 400, 500 and
800 mgm2 DTIC groups respectively.
Tumour response and toxicity assessment used the World
Health Organization (WHO) criteria (WHO, 1979). Complete
response was defined as the disappearance of all known
disease for at least 4 weeks; partial response was defined as a
reduction in the sum of the products of the largest perpen-
dicular diameters of each lesion by at least 50% for at least 4
weeks; stable disease was defined as a decrease of less than
50% in total tumour size, or an increase of less than 25% in
the size of one or more lesions. Toxicity was recorded and
analysed using the WHO grading system.
Lung function tests were also performed in 11 patients
following the development of an adult respiratory distress
type syndrome in one patient. The tests were performed at
the Lung Function Unit at Wythenshaw Hospital, Man-
chester. Routine spirometry was performed using a Gould
Pulmonet III Spirometer (cardiokinetics, Salford, UK). Total
lung capacity was measured by body plethysmography (Eric
Jaeger (UK) Ltd). Carbon monoxide transfer factor was
measured by the single breadth method (PK Morgan Ltd,
Chatham, UK).
Results
Comparability ofdifferent DTIC dosage groups
As shown in Table I, the three treatment groups were well
balanced with no statistical differences (chi-squared tests) in
pretreatment characteristic in terms of distributions of age,
sex, performance status, number of metastatic organ sites
involved, prior radiotherapy or chemotherapy and number of
treatment cycles given.
Responses
In the 60 patients studied, the overall response rate was 30%
with 18 patients responding to therapy: when based on the
different treatment groups, the mean response rates were
24%, 30% and 40% in patients receiving 400, 500 and
800mgm-2 of DTIC respectively (Table II). Despite this
apparently linear DTIC dosage-dependent clinical response
rate, there was no statistically significant difference in res-
ponse with different DTIC dosage levels (P = 0.29, test for
linear trend). Two complete responders were seen in patients
receiving 400mgm-2 and one in patients receiving 500mg
m_2. Four patients had stable disease and fifteen patients had
partial response. The median duration of chemotherapy re-
sponse was 5 months (range, 1-9 months). The sites of
response for the metastatic sites available is shown in Table
III.
Haematological toxicity
Table IV shows the haematological toxic effects seen with
different DTIC dosage. Severe anaemia (WHO > grade 3),
neutropenia (WHO > grade 3) and thrombocytopenia
(WHO > grade 3) occurred more often with higher dosage
DTIC and this was statistically significant. Anaemia was seen
more often in the later treatment cycles (after cycle 2) than
early treatment cycles.
Pulmonary toxicity
One patient with disseminated lymphadenopathy responding
to chemotherapy died from an acute respiratory distress type
syndrome. This patient received 500 mg m-2 DTIC and
100 mg m-2 fotemustine. The history was of 10 days dry
cough and increasing breathlessness. The CXR showed a
bilateral alveolar shadowing and echocardiogram demon-
Table I Comparison of patients characteristics
DTIC Dosage (mgm-2)
400 500 800 P-valuea
Patients (n) 25 20 15
Sex (M/F) 13/12 11/9 4/11 P=0.2
KP (>70/<70) 22/3 17/3 11/4 P=0.09
Age (>40 yrs/<40 yrs) 21/4 16/4 12/3 P=0.96
Previous CT (no/yes) 23/2 15/5 10/5 P = 0.12
Previous RT (no/yes) 21/4 15/5 11/4 P = 0.66
No of metastatic sites P = 0.37
1 6 5 1
2 12 4 6
3 4 5 5
>4 3 5 3
No of CT courses given P= 0.84
1 3 3 4
2 8 6 4
3 6 7 3
>4 8 4 4
a =chi-squared test. CT = chemotherapy. RT = radiotherapy.
Table II Comparison of response rates
DTIC Dosage (mgm-2)
Response 400 500 800 Total
Progression 18 (68%) 13 (65%) 7 (47%) 33
Stable 1 (4%) 1 (5%) 2 (13%) 4
Partial response 4 (16) 5 (25%) 6 (40%) 15
Complete response 2 (8%) 1 (5%) 0 (0%) 3
Patients (number) 25 20 15 60
() % based on total patient number in each treatment group.
Table III Metastatic sites and response with different DTIC
doses
No ofpatients with DTIC Dosage (MgM-2)
metastatic sitesa 400 500 800 Total
Non-visceral sites only 1 (1) 2 (1) 2 (2) 5 (4)
Visceral sites only 11 (3) 6 (1) 4 (1) 21 (7)
Both 13 (2) 12 (4) 9 (4) 34 (5)
ap>0.5, chi-squared test. () number in bracket denotes number of
patients responding.
Table IV Haematological toxicity for each DTIC dose
DTIC Dose (mg/m-2)
Toxicity WHO grade 400(25 pts) 500(20 pts) 800(15 pts) P-value"
Number ofpatients
Anaemia 2 5 (20%) 2 (10%) 5 (33%)
>3 1 (4%) 4 (20%) 5 (33%) <0.05
Leucopenia 2 1 (4%) 4 (20%) 3 (20%)
>3 1(4%) 2 (10%) 6 (40%) <0.01
Platelets 2 2 (8%) 2 (10%) 1 (7%)
> 3 0 (0%) 4 (20%) 6 (40%) 0.0005
a = chi-squared test. () % based on total patient number in each treatment group.1358 S.-M. LEE et al.
Table V Physiological results of respiratory function test
FEVI VC TLV RV DLCO KCO
Patient % PreT % PreT % PreT % PreT % PreT % PreT
MBC2 a 95.3 93.2 102.9 112 91.3 97
MSC3 102.7 102.6 98.2 106.8 75.3 77.6
SSc3 101.5 93.7 94.8 78.3 79.2 66
IPO 100 87.5 80.5 70.6 84.3 94.8
LPC4 100 88.5 69.8 51.6 54.5 44
PH' 94.7 99 100 100 73.7 78.8
HGC4 91 90.8 82 86 74.4 56.5
RLC4 76.5 89.6 73 58.9 100 85.7
CWc4 60.3 59 65.1 83.2 50.5 88.4
LDC5 100 100 93.8 94.9 70.1 89.1
WLC6 105 89.7 98.2 100 69.5 80
P value 0.249 0.004 0.010 0.035 0.0002 0.0035
%PreT = Per cent of prechemotherapy value. apll patients received
400 mg m2 DTIC and 100 mg m-2 fotemustine and number after patient's
initial refers to treatment cycle. FEV1 = Forced expiratory volume in one
second; VC = Vital capacity; TLC = Total lung capacity; RV = Residual
volume; DLCO = total lung carbon monoxide transfer corrected for
haemoglobin; KCO = transfer coefficient. P value: based on one-sample
t-test.
strated a normal left ventricular function with no evidence of
pericardial effusion. Bronchial alveolar-lavage produced fluid
containing inflammatory cells. Despite high dose steroid and
septrin, the patient condition's continued to deteriorate and
death occurred 10 days after presentation. Post-mortem
showed features of those of adult respiratory distress syn-
drome with interstitial fibrosis.
Following this case, the treatment protocol was amended
and the DTIC dosage was reduced to 400 mg m-2 with
fotemustine maintained at 100 mg m-2. A full lung function
assessment was undertaken in 11 patients before and after
chemotherapy. Table V shows the physiological results of
patients studied. Data was expressed as percentage of pre-
treatment results. As shown in the table, significant reduction
of vital capacity (VC), total lung volume (TLV), residual
volume (RV), total lung carbon monoxide transfer (DLCO)
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Figure 1 Survival to different dosages of DTIC with fotemustine
maintained at 100 mg m-2.
therapy. No relationship was seen between the extent of
pulmonary damage and treatment cycles (P= 0.72, one-
sample t-test). One patient (LPC4, Table V) presented with an
acute onset of breathlessness and investigations revealed
restrictive spirometry and small lung volumes associated with
reduced total lung carbon monoxide transer (DLCO of
54.5% of prechemotherapy value) and transfer coefficient
(KCO of 44% of prechemotherapy value). CXR showed
patchy upper lobe shadowing that was more marked on the
right hand side.
Other toxicity
Nausea and vomiting (> WHO 3) occurred in 14 patients
despite metoclopramide, elevated transaminases in ten pa-
tients, elevated alkaline phosphatases in 12 patients and
elevated bilirubin in five patients and these were not statis-
tically different between the three treatment groups. Two
infective episodes were noted in two patients receiving 500
mgM-2 DTIC and in three patients receiving 800mgm2
DTIC.
Survival
The overall median survival was 3.6 months (range, 1-15
months). Within the treatment subgroups, median survivals
were 6.3 months, 2.75 months and 3.6 months in patients
receiving 400, 500 and 800 mg m-2 DTIC respectively. How-
ever, no statistically significant difference in survival was seen
between the different DTIC doses (P = 0.67, log-rank test;
see Figure 1). Nine patients are alive at 5 to 26 months
(median 10 months); three patients with no tumour and five
patients with stable disease. There was a statistically
significant difference (P<0.0001 log-rank test) between sur-
vival for responders (median survival, 9 months; including
patients with stable disease) compared to patients with pro-
gressive disease (median survival, 2.9 months).
Discussion
The current study reports an overall response rate of 30%
obtained with sequential DTIC then fotemustine. Although
there appeared to be a trend towards a higher response rate
with increasing dosage of DTIC this was not statistically
significant and may be due to the small number of patients
entered to each treatment group. The majority of studies in
which DTIC has been given by single i.v. bolus or daily
injections over 5 days, have produced an overall response
rate of about 20% (Comis 1976; Mastrangelo et al., 1982;
Geeraerts & Nathanson, 1986; Balch et al., 1989). Single
doses of DTIC of 850mgm-2 (Samson et al., 1978) and
6co 0
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800 mg m-2 with dactinomycin (Hochster et al., 1985) or
250 mg m-2 daily for 5 days with dactinomycin (Robidoux et
al., 1982) gave response rates of 23%, 22% and 15% respec-
tively. Fotemustine alone gave a response rate of about 24%
(Jacquillat et al., 1990). Therefore the overall response rate of
30% achieved with the current study would support the use
of a combination of DTIC and fotemustine, although, be-
cause of the absence of a direct comparison, no conclusions
about the scheduling can be reached. In one study of 18
patients treated with combined fotemustine/DTIC chemo-
therapy, giving fotemustine (100 mgm-2) I h prior to DTIC
not only had no clinical effect but also caused unexpected
antagonism and modification of the pattern oftoxicity (Aam-
dal et al., 1990) and supports the use of our administration
schedule. If the trend towards a higher response rate with
higher dosage DTIC is substantiated with larger number of
patients, it is not unreasonable to suggest that it may be
related to the increasing extent of ATase depletion achieved
in tumour tissue assuming that a depletion is similar to that
occurring in lymphocytes (Lee et al., 1991). However, with
the dosages of DTIC used in the current study, complete
suppression of lymphocyte ATase was not acheived; the
mean nadir ATase activities were approximately 56%, 27%
and 24% of the pretreatment activity in patients receiving
400, 500 and 800 mg m2 of DTIC (Lee et al., 1993). If this
is reflected in the tumour cells, residual ATase activity fol-
lowing DTIC administration may be sufficient to repair any
potentially toxic 06-chloroethyguanine lesions induced by the
subsequent administration of a chloroethylating agent. The
lymphocyte ATase depletion data (Lee et al., 1991; Lee et al.,
1993) suggest that it would be interesting to explore whether
or not pulsed DTIC treatment every 4 h or continuous DTIC
infusion, followed or not by fotemustine or another nitro-
sourea will be able to improve the response rate, since an
improved clinical response might be achieved if complete
tumour ATase suppression is attained prior to fotemustine
administration.
An interesting finding was the statistically significant rela-
tionship seen between the development of severe haemato-
logical toxicity and the dosage of DTIC administered. In one
study of 46 patients treated with 850 mgm-2 DTIC given as
single i.v. bolus, thrombocytopenia ( 100,000 ml-') and
leucopenia (S 1000 ml-') was uncommon and developed in
only 4% and 2% of the treatment courses (Pritchard et al.,
1980). In contrast, in the present study this occurred in 40%
and 53% of the patients receiving sequential 800 mg m2
DTIC and lOOmgm2 fotemustine. A more extensive mar-
row toxicity was seen in the schedule using 800mgm2 of
DTIC and one possible explanation for this might be due to
a more extensive ATase depletion of the already low levels of
ATase in the marrow (Gerson et al., 1985) resulting in an
increased sensitivity to fotemustine or subsequent doses of
DTIC. In this context, ATase-deficient murine haematopoi-
etic stem cells transfected with and expressing bacterial
ATase genes are highly resistant to the toxic effects of
methylating and chloroethylating agents strongly suggesting
that endogenous ATase expression would protect against the
haematological effects of these agents (Jelinek et al., 1988)
and hence ATase depletion would result in sensitisation.
Furthermore, these is some experimental evidence to indicate
that ATase depletion of nitrosourea-resistant melanoma cells
with 06-methylguanine not only sensitises the tumour cells
but also the normal bone marrow cells following subsequent
exposure to a chloroethylating nitrosourea (Dempke et al.,
1987).
Another interesting finding was the occurrence of pul-
monary toxicity. Two patients presented with an acute short-
ness of breath; one died and post-mortem revealed features
of adult respiratory distress syndrome with interstitial fi-
brosis. The second patient responded to high dose steroid;
investigations showed a small lung volume with significantly
reduced carbon monoxide transfer factor. Follow-up studies
in another 10 patients showed a significant sub-clinical
deterioration in lung function following chemotherapy (Table
V). The clinical, radiological and histological features of
'early onset' lung fibrosis have previously been described with
BCNU and other nitrosoureas (Bailey et al., 1978; Durant et
al., 1979; Aronin et al., 1980; Sekler et al., 1980; Weiss et al.,
1981); correlation is seen when cumulative dosage of BCNU
> 1000mgm2 (Weiss et al., 1981). However, the two cases
of interstitial pneumonitis in our study received a cumulative
dosage of < 400mg m-2 of fotemustine suggesting that the
synergy between DTIC and fotemustine (as used in the
schedule here) may be responsible for the acute pulmonary
event, possibly related to greater cytotoxicity in normal lung
cells following depletion of the endogenous ATase. A recent
phase II study of fotemustine alone in 153 patients with
disseminated melanoma was not associated with any pul-
monary toxicity and similar finding was reported in another
38 patients with gliomas treated with fotemustine alone (Jac-
quillat et al., 1990; Frenay et al., 1991). Lung tissue has a
relatively low ATase activity in comparison with other tissues
(Grafstrom et al., 1984; Gerson et al., 1986) and as a result
they may be more sensitive to the cytotoxic effects of DNA
alkylation. This may be a particular problem in those
patients whose lung tissue has low ATase activity or in which
ATase depletion by DTIC has been more effective.
In conclusion, sequential DTIC and fotemustine appears to
be more effective than DTIC or fotemustine alone. There is a
trend towards increased response rate with higher dosage
DTIC however, if this is confirmed in a larger group of
patients it has been achieved whilst eliciting significantly
increased haematological and possibly puhnonary toxicity.
The median survival time remains short in these patients with
advanced disease, but we might speculate that further inves-
tigations using different schedules of DTIC combined with a
nitrosourea to overcome ATase-mediated drug resistance
could be worthwhile particularly if an increased response is
achieved in the absence of increased toxicity because of
general ATase depletion in both normal and tumour tissues.
Whether the marrow toxicity can be reduced with the help of
haemopoietic growth factors would require further explora-
tion. The subclinical pulmonary damage observed indicates
that it is of considerable importance to monitor these
patients to prevent the possibility of acute and/or long term
lung damage. Nevertheless, the present study provides a
framework for other investigations using ATase depleting
agents such as a methylating agents or 06-benzylguanine
before administering chloroethylating nitrosoureas.
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